| Date | Title | Description |
| 19.06.2025 | Corvia Medical: $55 Million Raised For Treating Heart Failure | Corvia Medical, a company dedicated to transforming the treatment of heart failure, announced the closing of a $55 million funding round from its existing investment syndicate, which includes Third Rock Ventures, General Catalyst Partners, ... |
| 18.06.2025 | Corvia Medical Secures $55 Million to Revolutionize Heart Failure Treatment | In a significant move for heart failure treatment, Corvia Medical, Inc. has successfully closed a $55 million funding round. This funding comes from a group of existing investors, including Third Rock Ventures, General Catalyst Partners, Ac... |
| 17.06.2025 | Corvia Medical Raises $55M in Funding | Corvia Medical, Inc, a Tewksbury, MA-based company dedicated to improve the treatment of heart failure, raised $55M in funding.
Backers included Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and two investors.
T... |
| 17.06.2025 | Corvia Medical closes $55 million funding round to complete confirmatory trial and pursue FDA approval of Corvia Atrial Shunt | Existing investors provide funding to finish international RESPONDER-HF trial
TEWKSBURY, Mass., June 17, 2025 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the succe... |
| 21.12.2024 | Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards | Commercial validation in Europe parallels ongoing RESPONDER-HF clinical trial
TEWKSBURY, Mass., Dec. 21, 2024 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, announced today that it ... |
| 25.10.2024 | Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients | 44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt
TEWKSBURY, Mass., Oct. 25, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transfo... |
| 08.05.2024 | Newly Published Data in JAMA Cardiology Demonstrates Favorable Long-term Effects of the Corvia Atrial Shunt in Heart Failure Patients | Two years of echocardiographic data affirm positive effects of atrial shunt therapy on heart structure and function
TEWKSBURY, Mass., May 8, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of hear... |
| 07.05.2024 | Newly Published Data in JAMA Cardiology Demonstrates Favorable Long-term Effects of the Corvia Atrial Shunt in Heart Failure Patients | Two years of echocardiographic data affirm positive effects of atrial shunt therapy on heart structure and function
TEWKSBURY, Mass., May 7, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of hear... |
| 12.04.2024 | Corvia's RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data | Second major trial for atrial shunt therapy demonstrates importance of patient selection
TEWKSBURY, Mass., April 12, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ... |
| 22.05.2023 | CORVIA MEDICAL RELEASES TWO-YEAR CLINICAL TRIAL RESULTS CONFIRMING SUSTAINED BENEFIT AND SAFETY OF ITS ATRIAL SHUNT IN HEART FAILURE PATIENTS | FIRST-EVER PHASE III RANDOMIZED CONTROLLED TRIAL OF ATRIAL SHUNT THERAPY SHOWS CONTINUED PROMISE
TEWKSBURY, Mass., May 22, 2023 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today a... |
| 06.12.2022 | CORVIA MEDICAL ANNOUNCES RANDOMIZATION OF FIRST PATIENT IN THE RESPONDER-HF CONFIRMATORY TRIAL | Corvia® Atrial Shunt has the potential to change the way heart failure is treated
TEWKSBURY, Mass., Dec. 6, 2022 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the fi... |
| 14.06.2022 | Corvia Medical Closed $54 Million Financing to Support Planned Confirmatory Trial of the Corvia® Atrial Shunt | Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients |
| 13.06.2022 | Corvia Medical Closes USD54M Funding | Corvia Medical, a Tewksbury, MA-based company dedicated to transforming the treatment of heart failure (HF), raised USD54M in funding.
Backers included Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and Edwards L... |
| 09.06.2022 | Corvia Medical closes $54M financing to support atrial shunt | The Corvia atrial shunt [Image from Corvia Medical]Corvia Medical announced today that it closed a $54 million equity financing from its existing investor syndicate.
Tewksbury, Massachusetts–based Corvia Medical earmarked the funds to suppo... |
| 09.06.2022 | Corvia Medical Raises $54M |
TEWKSBURY, MA, Corvia Medical today announced the closing of a $54 million equity financing from its existing investor syndicate.
>> Click here for more funding data on Corvia Medical
>> To export Corvia Medical funding data... |
| 01.04.2022 | REDUCE LAP-HF II ANALYSES SHOW 50% OF STUDY PATIENTS DEMONSTRATED SIGNIFICANT CLINICAL BENEFIT FROM THE CORVIA® ATRIAL SHUNT | Landmark trial advances understanding of which HFpEF patients may benefit from atrial shunt therapy
TEWKSBURY, Mass., April 1, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF)... |
| 02.02.2022 | LANDMARK REDUCE LAP-HF II TRIAL DEMONSTRATES CLINICAL BENEFIT OF CORVIA® ATRIAL SHUNT IN LARGE SEGMENT OF HEART FAILURE PATIENTS | REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy
TEWKSBURY, Mass., Feb. 2, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today an... |
| 01.02.2022 | LANDMARK REDUCE LAP-HF II TRIAL DEMONSTRATES CLINICAL BENEFIT OF CORVIA® ATRIAL SHUNT IN LARGE SEGMENT OF HEART FAILURE PATIENTS | REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy
TEWKSBURY, Mass., Feb. 1, 2022 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today an... |
| 17.11.2020 | Corvia Medical Completes Randomization In REDUCE LAP-HF II Pivotal Trial And Gains FDA Authorization To Provide Continued Access For The Corvia Atrial Shunt | TEWKSBURY, Mass., Nov. 17, 2020 /PRNewswire/ — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), today announced completion of randomization in its REDUCE LAP-HF II global, pivotal trial. The tri... |
| 14.01.2020 | Corvia Medical’s Global Clinical Trial Begins Randomization in Japanese Patients | TEWKSBURY, Mass. /PRNewswire/ — Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the first Japanese patients were randomized in Toyama and Hyogo under a cli... |
| 09.10.2019 | Corvia Medical’s Interatrial Shunt Device (IASD®) Receives Breakthrough Device Designation for Heart Failure | TEWKSBURY, MA – Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device d... |
| 12.09.2019 | Corvia Medical & PhysIQ Partner in Phase 3 Heart Failure Clinical Trial | Corvia Medical is actively enrolling and sponsoring a first-of-its-kind 100+ site, global, Phase 3 clinical trial leveraging continuous multivariate wearable sensor data and artificial intelligence (AI) based analytics to evaluate the clini... |
| 11.03.2019 | Edwards Lifesciences announces exclusive right to acquire Corvia Medical, Inc. | IRVINE, Calif., — Edwards Lifesciences Corporation EW, -0.99% the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with st... |
| 27.08.2018 | Corvia Medical Announces Strong Positive One-Year Data From REDUCE LAP-HF I Randomized, Sham-Controlled Clinical Trial | Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced one-year follow-up data from the REDUCE LAP-HF I clinical study of its Interatrial Shunt Device (IASD®). Th... |
| 12.05.2016 | Corvia Medical Announces CE Mark Approval And Enrollment Of First Patients In Randomized Clinical Study | TEWKSBURY, Mass., May 12, 2016 /PRNewswire/ — Corvia Medical, Inc., a privately-held medical device company that has developed a first-in-class structural heart device to treat heart failure, today announced CE Mark approval of its InterAtr... |
| - | Corvia Medical | “The Corvia® Atrial Shunt is designed to reduce symptoms associated with heart failure (HF), reduce HF hospitalizations, and improve quality of life.” |
